Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Valsamo Anagnostou"'
Autor:
Malcolm V. Brock, Benjamin Levy, Jillian Phallen, Matthew D. Hellmann, Victor E. Velculescu, Doreen N. Palsgrove, I K Ashok Sivakumar, Edward Gabrielson, Qing Kay Li, Christine L. Hann, Lamia Rhymee, Valsamo Anagnostou, Peter B. Illei, Patrick M. Forde, Kristen A. Marrone, Alessandro Leal, Josephine Feliciano, Jarushka Naidoo, Daniel C. Bruhm, Franco Verde, James M. Isbell, James R. White, Carolyn Hruban, Janis M. Taube, Tricia R. Cottrell, Robert B. Scharpf, Vilmos Adleff, Drew M. Pardoll, Julie R. Brahmer, Christos S. Georgiades, Rachel Karchin, Noushin Niknafs, Jennifer L. Sauter, Jamie E. Chaft, Kellie N. Smith, Samuel Rosner
Publikováno v:
Cancer Research. 79:1214-1225
Despite the initial successes of immunotherapy, there is an urgent clinical need for molecular assays that identify patients more likely to respond. Here, we report that ultrasensitive measures of circulating tumor DNA (ctDNA) and T-cell expansion ca
Autor:
Valsamo Anagnostou, R. Santana-Davila, A. Shivakumar, Z. Sun, Patrick M. Forde, Xiaoshan M. Shao, Victor E. Velculescu, Peter B. Illei, Hedy L. Kindler, Julie R. Brahmer, C. Cherry, Arkadiusz Z. Dudek, A. Balan, Zineb Belcaid, Hossein Borghaei, Mara Lanis, James R. White, S.S. Ramalingam, Kellie N. Smith, Rachel Karchin, Noushin Niknafs, T. Purcell
Publikováno v:
Journal of Thoracic Oncology. 16:S867-S868
Autor:
Kristen A. Marrone, Samuel Rosner, Jenna Van Liere Canzoniero, David S. Ettinger, Alexandria Curry, Benjamin Levy, Julie R. Brahmer, Valsamo Anagnostou, Patrick M. Forde, Mara Lanis, Michael Hwang, Gavin Pereira, Tanguy Seiwert, Guangfan Zhang, Victor E. Velculescu, Joshua E. Reuss, Christine L. Hann, Lamia Rhymee, Vincent K. Lam, Jarushka Naidoo
Publikováno v:
Cancer Research. 81:27-27
Background: Treatment-induced anti-tumor immune response may be reflected in peripheral blood leukocyte composition and shifts. The relative abundance of immune cell subsets captured by neutrophil-to-lymphocyte ratio (NLR) is a promising biomarker of
Autor:
Joseph C. Murray, Valsamo Anagnostou
Publikováno v:
Nature Reviews Clinical Oncology. 18:65-66
Noninvasive liquid biopsy assays integrating tumour and immune biomarkers are a promising tool to enhance clinical decision-making in immuno-oncology. Here, we discuss how circulating tumour DNA dynamics, in conjunction with pre-treatment tumour and
Autor:
Mara Lanis, Victor E. Velculescu, Stephen C. Yang, Vincent K. Lam, Kristen A. Marrone, Ronan J. Kelly, Heather Schneider, Richard J. Battafarano, Blair A. Jobe, Hanika Rodavia, Zineb Belcaid, Stephen R. Broderick, Archana Balan, Elizabeth D. Thompson, Ali H. Zaidi, Benjamin Levy, Christopher Cherry, Valsamo Anagnostou, Josephine Feliciano, Jinny Ha
Publikováno v:
Journal of Clinical Oncology. 39:4042-4042
4042 Background: Improving immunotherapy efficacy remains an unmet need in esophagogastric cancer and a deeper understanding of tumor and immune system dynamics during therapy may tailor immuno-oncology approaches. Methods: We performed whole exome s
Autor:
Jillian Phallen, Malcolm V. Brock, Patrick M. Forde, Stephen B. Baylin, Cynthia A. Zahnow, Theresa Zhang, Peter B. Illei, Violeta Beleva Guthrie, Victor E. Velculescu, Vilmos Adleff, Valsamo Anagnostou, Qing Kay Li, James R. White, Neha Wali, Rohit Bhattacharya, Franco Verde, Kellie N. Smith, Robert B. Scharpf, Carolyn Hruban, Kristen Rodgers, Drew M. Pardoll, Rachel Karchin, Julie R. Brahmer, Christos S. Georgiades, Noushin Niknafs, Edward Gabrielson, Hyunseok Kang, Jarushka Naidoo, William H. Sharfman
Publikováno v:
Cancer discovery, vol 7, iss 3
Immune checkpoint inhibitors have shown significant therapeutic responses against tumors containing increased mutation-associated neoantigen load. We have examined the evolving landscape of tumor neoantigens during the emergence of acquired resistanc
Autor:
Phuong Tran, Shailender Bhatia, Agustin Vega-Crespo, Adi Diab, Gabriel Abril-Rodriguez, Walter J. Urba, Anusha Kalbasi, Katie M. Campbell, F. Stephen Hodi, Valsamo Anagnostou, Michael J. Quist, Cristina Puig-Saus, Craig L. Slingluff, Jennifer Tsoi, Petra Ross-Macdonald, Catherine S. Grasso, Jedd D. Wolchok, Antoni Ribas, John B. A. G. Haanen, Drew M. Pardoll, Egmidio Medina, Christophe Martignier, Yeon Joo Kim, Suzanne L. Topalian, Daniel Sanghoon Shin, Salvador Martin Algarra, Davis Y. Torrejon, Victor E. Velculescu, Ameya Champhekar, Bartosz Chmielowski, William H. Sharfman, Megan Wind-Rotolo, Jason J. Luke, Douglas B. Johnson, Mykola Onyshchenko, Daniel E. Speiser
Publikováno v:
Cancer cell, vol 38, iss 4
Cancer Cell
Cancer cell, vol 39, iss 1
Cancer Cell
Cancer cell, vol 39, iss 1
SUMMARY: We analyze the transcriptome of baseline and on-therapy tumor biopsies from 101 patients with advanced melanoma treated with nivolumab (anti-PD-1) alone or combined with ipilimumab (anti-CTLA-4). We find that T cell infiltration and interfer
Autor:
Hua-Ling Tsai, Alexander S. Baras, Suzanne L. Topalian, Robert B. Scharpf, James R. White, John-William Sidhom, Zineb Belcaid, Daniel C. Bruhm, Valsamo Anagnostou, Noushin Niknafs, Petra Ross-Macdonald, Julie E. Stein, Drew M. Pardoll, Hao Wang, Megan Wind-Rotolo, Joseph C. Murray, Catherine S. Grasso, Antoni Ribas, Janis M. Taube, Victor E. Velculescu
Publikováno v:
Journal of Clinical Oncology. 38:10009-10009
10009 Background: The complex crosstalk between tumor and immune cells during immune checkpoint blockade mandates the development of integrated models to interpret the antitumor immune response and predict clinical outcome. Methods: We performed comp
Autor:
Ashok Sivakumar, Rohit Bhattacharya, Collin Tokheim, Rachel Karchin, Victor E. Velculescu, Violeta Beleva Guthrie, Valsamo Anagnostou
Binding of peptides to Major Histocompatibility Complex (MHC) proteins is a critical step in immune response. Peptides bound to MHCs are recognized by CD8+ (MHC Class I) and CD4+ (MHC Class II) T-cells. Successful prediction of which peptides will bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b53898d74e25649022156c2286b11ef
Autor:
Benjamin Levy, Jarushka Naidoo, Julie R. Brahmer, Kristen A. Marrone, Patrick M. Forde, Joshua E. Reuss, Victor E. Velculescu, Samuel Rosner, Valsamo Anagnostou, Christine L. Hann, Josephine Feliciano
Publikováno v:
Journal of Clinical Oncology. 37:105-105
105 Background: The use of immune targeted agents for NSCLC has improved outcomes for patients (pts) with metastatic disease. Biomarkers such as the neutrophil-to-lymphocyte ratio (NLR) prior to therapy have been shown to predict outcomes however lit